SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
JOIN US ON
HME-forum.com
HME Forum introduces Myeloma Connect
Please scan here to register for
the upcoming webinars
REGISTER AT
www.HME-forum.com/register
Click the “LOG IN”
button at the top of
the page
Indicate if you need
an account and
then fill out the
registration form
If you already have
a Janrain account,
please use your
username and
password to access
the HME Forum
Myeloma Connect 2021
Myeloma Connect 2021 is a series of live,
interactive broadcasts, each focusing on
a specific topic relevant to hematologists
treating patients with multiple myeloma.
Register your interest at: www.HME-forum.com
Registered participants will also be able to view archived
versions of the broadcasts following the live events.
Myeloma Connect Scientific Committee:
Michel Delforge
BELGIUM
Mohamad Mohty
FRANCE
Please note that all events are only open to healthcare professionals.
Registration prior to the live event is required in order to access both
the live and archived broadcasts.
Depending on your country, you may not have access to HME Forum.
Organised and supported by Janssen Pharmaceutical
Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, Belgium
EM52808
Date of preparation: February 2021
Copyright © 2021 Janssen
Pharmaceutica NV